These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 17976987)

  • 21. Anthranilamide inhibitors of factor Xa.
    Mendel D; Marquart AL; Joseph S; Waid P; Yee YK; Tebbe AL; Ratz AM; Herron DK; Goodson T; Masters JJ; Franciskovich JB; Tinsley JM; Wiley MR; Weir LC; Kyle JA; Klimkowski VJ; Smith GF; Towner RD; Froelich LL; Buben J; Craft TJ
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4832-6. PubMed ID: 17624775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Arylsulfonamides: a study of the relationship between activity and conformational preferences for a series of factor Xa inhibitors.
    Senger S; Convery MA; Chan C; Watson NS
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5731-5. PubMed ID: 16982192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.
    Shi Y; O'Connor SP; Sitkoff D; Zhang J; Shi M; Bisaha SN; Wang Y; Li C; Ruan Z; Lawrence RM; Klei HE; Kish K; Liu EC; Seiler SM; Schweizer L; Steinbacher TE; Schumacher WA; Robl JA; Macor JE; Atwal KS; Stein PD
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7516-21. PubMed ID: 22041058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors.
    Zbinden KG; Obst-Sander U; Hilpert K; Kühne H; Banner DW; Böhm HJ; Stahl M; Ackermann J; Alig L; Weber L; Wessel HP; Riederer MA; Tschopp TB; Lavé T
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5344-52. PubMed ID: 16213138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part II: exploration of 6-6 fused rings as alternative S1 moieties.
    Yoshikawa K; Kobayashi S; Nakamoto Y; Haginoya N; Komoriya S; Yoshino T; Nagata T; Mochizuki A; Watanabe K; Suzuki M; Kanno H; Ohta T
    Bioorg Med Chem; 2009 Dec; 17(24):8221-33. PubMed ID: 19900814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phenyltriazolinones as potent factor Xa inhibitors.
    Quan ML; Pinto DJ; Rossi KA; Sheriff S; Alexander RS; Amparo E; Kish K; Knabb RM; Luettgen JM; Morin P; Smallwood A; Woerner FJ; Wexler RR
    Bioorg Med Chem Lett; 2010 Feb; 20(4):1373-7. PubMed ID: 20100660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stereoselective synthesis and biological evaluation of 3,4-diaminocyclohexanecarboxylic acid derivatives as factor Xa inhibitors.
    Nagata T; Nagamochi M; Kobayashi S; Komoriya S; Yoshino T; Kanno H
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4587-92. PubMed ID: 18675545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Orally active factor Xa inhibitors: 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine derivatives.
    Haginoya N; Kobayashi S; Komoriya S; Hirokawa Y; Furugori T; Nagahara T
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2935-9. PubMed ID: 15125963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, and biological activity of novel factor Xa inhibitors: improving metabolic stability by S1 and S4 ligand modification.
    Komoriya S; Kobayashi S; Osanai K; Yoshino T; Nagata T; Haginoya N; Nakamoto Y; Mochizuki A; Nagahara T; Suzuki M; Shimada T; Watanabe K; Isobe Y; Furugoori T
    Bioorg Med Chem; 2006 Mar; 14(5):1309-30. PubMed ID: 16263291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of R-142086 as a factor Xa (FXa) inhibitor: syntheses and structure-activity relationships of cinnamyl derivatives.
    Noguchi T; Tanaka N; Nishimata T; Goto R; Hayakawa M; Sugidachi A; Ogawa T; Niitsu Y; Asai F; Ishizuka T; Fujimoto K
    Chem Pharm Bull (Tokyo); 2009 Jan; 57(1):22-33. PubMed ID: 19122312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part I: exploration of 5-6 fused rings as alternative S1 moieties.
    Yoshikawa K; Yokomizo A; Naito H; Haginoya N; Kobayashi S; Yoshino T; Nagata T; Mochizuki A; Osanai K; Watanabe K; Kanno H; Ohta T
    Bioorg Med Chem; 2009 Dec; 17(24):8206-20. PubMed ID: 19884015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants.
    Lam PY; Clark CG; Li R; Pinto DJ; Orwat MJ; Galemmo RA; Fevig JM; Teleha CA; Alexander RS; Smallwood AM; Rossi KA; Wright MR; Bai SA; He K; Luettgen JM; Wong PC; Knabb RM; Wexler RR
    J Med Chem; 2003 Oct; 46(21):4405-18. PubMed ID: 14521405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
    Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
    J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors.
    Watson NS; Brown D; Campbell M; Chan C; Chaudry L; Convery MA; Fenwick R; Hamblin JN; Haslam C; Kelly HA; King NP; Kurtis CL; Leach AR; Manchee GR; Mason AM; Mitchell C; Patel C; Patel VK; Senger S; Shah GP; Weston HE; Whitworth C; Young RJ
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3784-8. PubMed ID: 16697194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
    Willardsen JA; Dudley DA; Cody WL; Chi L; McClanahan TB; Mertz TE; Potoczak RE; Narasimhan LS; Holland DR; Rapundalo ST; Edmunds JJ
    J Med Chem; 2004 Jul; 47(16):4089-99. PubMed ID: 15267248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 7-fluoroindazoles as potent and selective inhibitors of factor Xa.
    Lee YK; Parks DJ; Lu T; Thieu TV; Markotan T; Pan W; McComsey DF; Milkiewicz KL; Crysler CS; Ninan N; Abad MC; Giardino EC; Maryanoff BE; Damiano BP; Player MR
    J Med Chem; 2008 Jan; 51(2):282-97. PubMed ID: 18159923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties.
    Corte JR; Fang T; Pinto DJ; Han W; Hu Z; Jiang XJ; Li YL; Gauuan JF; Hadden M; Orton D; Rendina AR; Luettgen JM; Wong PC; He K; Morin PE; Chang CH; Cheney DL; Knabb RM; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2008 May; 18(9):2845-9. PubMed ID: 18424044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Substituted thiophene-anthranilamides as potent inhibitors of human factor Xa.
    Kochanny MJ; Adler M; Ewing J; Griedel BD; Ho E; Karanjawala R; Lee W; Lentz D; Liang AM; Morrissey MM; Phillips GB; Post J; Sacchi KL; Sakata ST; Subramanyam B; Vergona R; Walters J; White KA; Whitlow M; Ye B; Zhao Z; Shaw KJ
    Bioorg Med Chem; 2007 Mar; 15(5):2127-46. PubMed ID: 17227710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.
    Mederski WW; Dorsch D; Anzali S; Gleitz J; Cezanne B; Tsaklakidis C
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3763-9. PubMed ID: 15203158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SAR and factor IXa crystal structure of a dual inhibitor of factors IXa and Xa.
    Smallheer JM; Alexander RS; Wang J; Wang S; Nakajima S; Rossi KA; Smallwood A; Barbera F; Burdick D; Luettgen JM; Knabb RM; Wexler RR; Jadhav PK
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5263-7. PubMed ID: 15454208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.